Archives: Agenda

Seedlip founder and game changer Ben Branson, takes on 10 quick fire questions from Jonathan Ford, co-founder of Pearlfisher and Rosalind Michaluk, Strategy Director at Pearlfisher — the creative force behind Seedlip’s iconic branding — to uncover what the past 10 years tells us about the next.

• Nootropics are the New Buzz: How brain-boosting ingredients are creating a white space for brands, and what makes nootropics different from other functional claims
• Bridging Science & Storytelling: Practical ways to educate consumers on complex ingredients without losing the ritual and fun of the drinking occasion
• From Ingredient to Icon: What it takes for a mind-enhancing beverage to stand out. Formulation, sourcing, regulatory guardrails, and flavour are all part of the brand promise
• Lessons from Kin: How we’ve navigated brand development, marketing, and community-building around cognitive function
• A Wellness Status Symbol: Why the next generation of drinkers sees cognitive wellness as the ultimate luxury, and how that shifts category strategy for innovators and suppliers alike
• Where We Go Next: What’s on the horizon for brands ready to push beyond mindful drinking into mind-bending territory

• Dives into GLP-1s and how this is changing beverage consumption
• It explores how GLP-1s are driving a shift from alcohol to soft drinks and how this impacts innovation
• Unpacks what innovation needs to look like for GLP-1 consumers – touching on hydration, greater functionality, taste innovation to deliver on consumer experiences

• How pharma can move digital health and digital diagnostics from pilots to scalable real-world solutions
• Key building blocks for adoption, including data, clinical evidence, technology development, and clinical workflow integration
• Practical lessons from real programs across screening, monitoring, and patient-centric digital tools

Visit our exhibitors’ booths throughout the 2 days and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple devices or Amazon gift cards. The Prize Draw will take place in the Exhibition Hall. Make sure you don’t miss out!

• Why tissue biopsies are sometimes essential in clinical trials for novel therapeutics
• Question-based framework to align tissue collection and analysis with clinical trial objectives and timelines
• Emerging biomarker technologies including digital pathology, artificial intelligence, and multiplex spatial biology

• Successfully managing a regulatory environment that varies by geography
• Mitigating risks associated with compliance and reducing the impact of delays in regulatory submissions on trial budgets and timelines
• Evolution of Project Optimus
• What is the status of harmonization of submissions in Europe?
• How conservative is the new FDA being how is the US administration set to further impact trials in 2027
• Do sponsors know where the gaps are in the latest ICH-GCP E6(R3) and how can AI help conduct gap analyses across SOPs and study documents

Moderator: Keya Watkins, President – Oncology, Worldwide Clinical Trials

• Overcoming financial constraints when budgets are limited and resources tight
• Building flexibility into outsourcing partnerships for scalability
• Fierce site competition: How start-ups can compete with established companies for sites
• Utilizing effective planning to improve study and program efficiency without compromising patient safety
• Agile and adaptable: Being prepared to adjust your strategy and approach as needed

Moderator: Keya Watkins, President – Oncology, Worldwide Clinical Trials